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A B S T R A C T
Adverse cutaneous reactions to itraconazole are known to be quite rare. We report a case of maculopapular reaction
caused by itraconazole. On the 7th day of itraconazole therapy for hand onychomycosis, in a 39-year-old woman pruritus
occurred with a subsequent morbiliform, symmetric, maculopapular eruption on the upper torso, neck, trunk and pres-
sure-bearing areas. Eruption progressed, becoming confluent and spreading to extremities. Due to increasing indicatio-
ns for the administration of itraconazole its increased usage as well as the possibility of allergic reactions should be ex-
pected even if these are a rare event.
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Introduction
Adverse cutaneous reactions to itraconazole are
known to be quite rare and are reported as rash and pru-
ritus1, acute generalized exanthematic pustulosis2, pho-
tosensitivity3, acute urticaria and angioedema4. Tucker
at al. described two patients with maculopapular erup-
tion in his review of 189 patients treated with itracona-
zole5. Here we report a case of maculopapular reaction
caused by itraconazole in a young female patient on the
7th day of itraconazole therapy.
Professional Report
A 39-year-old woman began oral treatment with itra-
conazole, 200 mg twice daily, for hand onychomycosis.
She reported no associated illnesses or other medication
usage. Her family and personal history were negative
and unremarkable for allergy. On the 7th day of itracona-
zole therapy pruritus occurred with a subsequent morbi-
liform, symmetric, maculopapular eruption on the upper
torso, neck, trunk and pressure-bearing areas. Eruption
progressed, becoming confluent and spreading to extre-
mities (Figure 1). Laboratory evaluation including im-
munologic workup revealed no abnormalities. Other cau-
ses of maculopapular cutaneous reactions were excluded,
such as acute viral and bacterial infections, collagen vas-
cular diseases, serum sickness-like reactions. Diagnosis
of allergic drug eruption has been suggested. Patohistolo-
gy of the skin biopsy showed a focal parakeratosis, dyske-
ratosis, mild spongiosis and basal cell liquefactive degen-
eration with lymphocytic exocytosis, a few eosinophils
and some red cell extravasation in the dermis, speaking
in the favor for diagnosis of adverse drug reaction.
Itraconazole therapy was discontinued and the patie-
nt was treated with topical and systemic corticosteroids
and systemic antihistamins. The rash resolved during
the next few days. Following the rash resolution allergo-
logic testing was suggested but refused by the patient.
Discussion
Itraconazole is a broad-spectrum oral triazole synthe-
sized in 1980. The mechanism of action is similar to ot-
her azoles and is primarily fungistatic. Itraconazole
shows less toxicity than the imidazole antifungals. Side
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effects most frequently reported include nausea, vomit-
ing, abdominal pain, diarrhea, anorexia, headache, dizzi-
ness, fatigue, fever and elevation of liver enzymes.
Maculopapular exanthem is the most common type of
drug-induced cutanous reaction. Often, it has a characte-
ristic structure, beginning with the lesions on the upper
torso or head and neck6 lesions becoming confluent, cov-
ering large areas of the body in symmetrical pattern, like
in our patient.
Firmly establishing a causal reaction between the
suspected agent and resulting cutaneous reaction is cru-
cial. Other important factors that contribute to the accu-
rate diagnosis of drug-induced cutaneous reactions are
establishing a chronological relation between suspected
drug and the reaction, noting improvement after cessa-
tion of the suspected agent. Most drug-induced maculo-
papular exanthemas usually appear 8–10 days after drug
therapy initiation, but can also appear earlier7 and later,
like in our case on the 7th day of therapy. Also, it is expec-
ted to fade within a similar period of time after medica-
tion withdrawal with or without systemic or local corti-
costeroid therapy.
The pathogenesis of exanthematous drug reactions is
not fully understood, although a cytotoxic T-cell-media-
ted reaction is likely in the majority of cases. The histolo-
gical features are often subtle but the characteristic
changes include lymphocytic exocytosis with mild spon-
giosis, accompanied by basal cell liquefactive degenera-
tion. In the dermis there is usually a perivascular lym-
phocytic infiltrate and variable number of eosinophils8,9,
like in our case.
Reactivation of the rash during re-challenge confirms
allergic reaction to suspected drug but in our case we
were not able to perform the testing. Confirmation of the
medical eruption with challenge test has been performed
previously in one case of maculopapular eruption7 and
acute urticaria and angioedema4.
Itraconazole has been widely used for onychomycosis
and dermatomycosis, especially as »pulse therapy«10 and
some suggested its effectiveness for seborrhoic dermati-
tis and atopic dermatitis as well11. Thus, due to increas-
ing indications for the administration of itraconazole its
increased usage should be expected, and with that in
mind itraconazole induced allergic reactions should be
considered as possibility when administering it in derma-
tology practices.
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Fig. 1. Maculopapular rash on the back of 39-year-old woman.
MAKULOPAPULOZNI OSIP NAKON TERAPIJE ITRACONAZOLOM
S A @ E T A K
Alergijske promjene ko`e kao posljedica uzimanja itrakonazola su rijetke. Prikazan je slu~aj makulopapularnog osi-
pa uzrokovanog itrakonazolom. Sedmog dana terapije itrakonazolom primijenjene radi onihomikoze ruku kod 39-godi-
{nje bolesnice, pojavio se svrbe` ko`e i morbiliformni, simetri~ni, makulopapulozni osip na ko`i dekoltea, vrata, trupa i
mjestima kompresije. Dolazi do progresije promjena, konfluiranja lezija i {irenja na ekstremitete. S obzirom na porast
indikacija za terapijsku primjenu itrakonazola mo`e se o~ekivati ~e{}a primjena ovoga lijeka kao i pojava alergijskih
reakcija premda se rijetko javljaju.
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